Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.61 |
| ▸ | ELOC | Q15369 | 14/20 | 0.59 |
| ▸ | ELOB | Q15370 | 14/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21068875 | 1.00 | VHL (0.61) | VHLELOCELOB | |
| SCHEMBL21068876 | 1.00 | VHL (0.61) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL23037225 | 0.99 | VHL (0.60) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL23037209 | 0.99 | VHL (0.60) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL23751723 | 0.99 | VHL (0.60) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL23751721 | 0.99 | VHL (0.60) | VHLELOCELOB | |
| SCHEMBL24376366 | 0.92 | VHL (0.60) | VHLELOCELOB | |
| SCHEMBL22632202 | 0.92 | VHL (0.60) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL23037237 | 0.92 | VHL (0.51) | VHLELOCELOB | |
| Hydrochloric Acid SCHEMBL23037319 | 0.92 | VHL (0.51) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3817745-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112714646-A | Protein tyrosine kinase 6(PTK6) degradation/disruption compounds and methods of use | 西奈山伊坎医学院 | 2021-04-27 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | VHL 554/4885ELOC 3466/4885ELOB 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.